Drug Profile
Mirvetuximab soravtansine - ImmunoGen
Alternative Names: Anti-FOLR1-monoclonal-antibody-maytansinoid-conjugate-IMGN-853; ELAHERE; IMGN-853; M9346A-sSPDB-DM4; M9346A-sulfo-SPDB-DM4; MIRV; Mirvetuximab soravtansine-gynxLatest Information Update: 29 Mar 2024
Price :
$50
*
At a glance
- Originator ImmunoGen
- Developer Hangzhou Zhongmei Huadong Pharmaceutical; ImmunoGen
- Class Antineoplastics; Drug conjugates; Immunotoxins; Maytansinoids; Monoclonal antibodies
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Phase II Endometrial cancer; Triple negative breast cancer
- No development reported Solid tumours
Most Recent Events
- 22 Mar 2024 US FDA grants full approval for mirvetuximab soravtansine for Ovarian Cancer, Fallopian tube cancer or Peritoneal cancer
- 12 Feb 2024 ImmunoGen has been acquired by AbbVie
- 09 Feb 2024 City of Hope Comprehensive Cancer Center in collaboration with National cancer Institute completes a phase I trial in Ovarian cancer, Fallopian tube cancer, Endometrial cancer, Peritoneal cancer and Triple-negative-breast cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Recurrent) in USA (IV) (NCT02996825)